INTRODUCTION
Breast cancer is the most common cancer among women of every major ethnic group in the United States. It is estimated that there are nearly three million women living in this country with a history of invasive breast cancer, and an additional 226,870 women were diagnosed in 2012 (1).
Although the incidence rate of Breast Cancer is lower in Black and Hispanic women (2) compared to White women, there are some serious disparities in breast cancer death rates among different ethnic groups. According to recent data, when evaluating outcome independently of stage at diagnosis, Black women with breast cancer have worse outcomes, and Hispanics, on the other hand, experience slightly improved outcomes compared with their White counterparts. (3) (4) (5) . Survival disparities found between those groups are poorly understood and probably stem from many causes.
Socioeconomic factors have been proposed to account to the poorer survival outcomes seen in those groups. It has been well described that Black and Hispanic women tend to be diagnosed with more advanced clinical stages (6-10). Lantz et al have shown that even after control for study site, age, and individual socioeconomic factors, the odds of early detection were still significantly less for Hispanic and Black women when compared to White women (9) .
Lower socioeconomic status among Black women has been assigned as one of the potential causes for the poor outcomes in this patient population (11). Nevertheless, similar pattern has been described among Hispanics (13) (14) (15) . This subtype of breast cancer correlates with a genetic signature of basal-like tumors, which is associated with aggressive histological features, BRCA mutation carriers and poor prognosis (14, 15) . Although early studies of BRCA mutations suggested that they were relatively rare among Black women (16) , many studies have found BRCA1 and more frequently BRCA2 mutations in this patient population (17, 18) . Other epidemiological factors in addition to differences in the tumor microenvironment and distinct genetic features have also been described in previous studies (19-21).
The factors contributing to the discrepancies in survival outcomes between Black, Hispanics and White patients are complex and could relate to both social and biologic differences. It is thus, of extreme importance to determine whether genetic differences play a role in this scenario as this could change the approach to decreasing the discrepancies in outcomes. One approach to identify potential targets mediating biologic differences between races is to compare RNA and protein expression in breast cancer tissue from patients of a variety of ethnicities.
The purpose of this study was to evaluate whether there were differences in gene or protein expression patterns between primary invasive breast cancers according to race/ethnicity and breast cancer subtype.
MATERIALS AND METHODS
Pretreatment fine-needle aspirations (FNA) specimens were collected during a prospective biomarker discovery study (LAB99-0402) and a prospective neoadjuvant Table S1 ) and signal amplified using a 3,3'-diaminobenzidine tetrachloride (DAB)-based DAKO signal amplification system (DAKO, Copenhagen, Denmark). A biotinylated secondary antibody was used as a starting point for signal amplification. Signal intensity was measured by scanning the slides and quantified with MicroVigene software (VigeneTech Inc., North Billerica, MA) to generate sigmoidal signal intensity-concentration curves for each sample.
Antibodies were selected based on markers currently used for breast cancer classification due to their value in treatment decisions, targets implicated in breast cancer signaling, and targets implicated in the signaling of the other cancer lineages, as well as the availability of high quality that passed a strict validation process.
Three hundred seventy-six FNA samples for gene expression analysis were collected into RNA and later stored at −80°C. Gene expression profiling was performed with Affymetrix U133A gene chips as previously described (22, 23) .
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The RPPA spot signal intensity data from MicroVigene were processed using the R package SuperCurve (http://bioinformatics.mdanderson.org/OOMPA), and normalized by a median polish method. Gene expression data sets were normalized with MAS5 algorithm, mean centered to 600 and log2 transformed before further analysis. We removed probe sets with average expression values less than the lowest 25% to reduce noise from low expressed probe sets.
As the first step of exploring how patients cluster by race, unsupervised hierarchical clustering (Pearson correlation, average linkage) across the RPPA data was conducted for each breast cancer subtype. Analysis of variance (ANOVA) test was performed to assess differential protein expression between races by each subtype, with false discovery rate corrected by using the beta-uniform mixture (BUM) model. Heat maps from unsupervised clustering analysis by breast cancer subtype are presented in Figure 1 showing no indication of an orderly pattern of races/ethnicities in the clustering. Furthermore, after multiplicity adjustment by applying a betauniform mixture (BUM) model to the P-values from the ANOVA test of race/ethnicity by breast cancer subtype, none of the 177 proteins was considered differentially expressed (FDR<0.05) among different races/ethnicities by breast cancer subtypes significant (Histograms presented in Supplemental Figure S1 ). Table 2 summarizes the P-values LS and KS permutation tests (from using BRB-Array Tools) showing no evidence of simultaneous protein expression differences between the different breast cancer subtypes according to race/ethnicity. Table 3 
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positive tumors showed differences according to race/ethnicity. However, validation in an independent set of 59 HER2-positive tumors across the significant 384 probes showed no pattern in the race comparisons (Supplemental Figure S3) .
Ingenuity Pathway Analysis (IPA) showed no obvious difference among races within breast cancer subtypes. The disease and disorder related pathways of each subtype are bar plotted in Figure 2 .
DISCUSSION
In summary, our results indicate that there are no large-scale gene and protein expression differences between breast cancers according to race/ethnicity and tumor subtype.
Previously, Grunda et al evaluated the expression of 84 genes involved in breast cancer prognosis, response to therapy, estrogen signaling, and tumor aggressiveness in age and stage matched paraffin-embedded breast cancer specimens form Black and White patients. They observed that twenty genes were differentially expressed between the two groups. Black women were significantly more likely to display aberrations in G1/S cell-cycle regulatory genes, decreased expression of cell-adhesion genes, and low to no expression estrogen pathway targets, which may confer a more aggressive behavior to the disease (20) .
A previous study also suggested that there might be differences in the tumor microenvironment between African-American (AA) and European-American (EA) breast cancer patients, with higher microvessel density and macrophage infiltration in AA compared with the European White population (21).
Other tumor genetic differences previously found between Black and White women that could help understand the differences in outcome include more frequent genome copy number gains and losses in Blacks (24), more prevalent expression of cyclin D1 (25), higher quantities of p16, p53, and cyclin E (14, 26, 27) AA patients, which had a significantly higher methylation index at the CDH13 locus than matched EA patients. No other methylation differences were found between the two patient population in the other five tumor suppressor genes studied, corroborating the hypothesis that these tumors do not demonstrate marked biological differences.
Finally, one cannot exclude that discrepancies in the treatment offered for Blacks and Hispanics had an impact on survival outcomes. AA patients frequently experience underuse of appropriate adjuvant therapy in clinical practice (32) , are less likely to complete therapy (33) and are more likely to experience a delay in the initiation of adjuvant chemotherapy (34, 35) . Evaluating outcome was out of the scope of this study, however; all the patients included were treated at our institution in a standard manner or as part of a clinical trial. Therefore it is very unlikely that the patients received suboptimal or differential therapies.
In order to fully appreciate our findings several strengths and limitations should be mentioned. To our knowledge, this is the first study that compared differences among racial/ethnic groups in a proteomic level. Other studies that previously evaluated the breast cancer genetic patterns between races did not use the same methodology.
Several studies have shown that RPPA technology is effective in mapping intracellular signaling networks in cell lines (28, (36) (37) (38) (39) ) and the use of this methodology is an advantage to our study.
We have included a large patient population that contains an important proportion of minority breast cancer patients. Even large gene-analyses like The Cancer Genome Atlas (TCGA) did not have good representation of minorities (40). By evaluating potential differences according to race/ethnicity according to tumor subtype, the number of patients in each category was relatively small and we were not able to perform subgroup analyses. In addition, the number of tumors analyzed does not allow us to confidently exclude small-scale expression differences in a limited number of proteins or RNAs. In our study, we did not examine the potential differential distribution of DNA nucleic acid polymorphisms, somatic mutations, gene rearrangements or copy number aberrations by race-ethnicity, which could account for biologic differences between ethnicities.
Our study is prone to the challenges associated with analysis according to race/ethnicity. We acknowledge that particularly Hispanics and Blacks represent heterogeneous populations where a mix of different ancestries is likely to exist. We were not able to obtain ancestry data and did not perform ancestry gene analysis. In addition, race/ethnicity was self-reported and we cannot rule out the presence of misclassification. Nevertheless, most of the studies that evaluated the outcomes between the different ethnicities used the same classification system as in our study.
In conclusion, based upon the data in this study, we were not able to detect significant variation in RNA or protein expression comparing different ethnicity groups of women with breast cancer. 
